Crossmark Global Holdings Inc. Lowers Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Crossmark Global Holdings Inc. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,709 shares of the company’s stock after selling 865 shares during the period. Crossmark Global Holdings Inc.’s holdings in IDEXX Laboratories were worth $1,534,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Chicago Partners Investment Group LLC grew its position in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after purchasing an additional 96 shares during the last quarter. National Pension Service boosted its holdings in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after acquiring an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC boosted its holdings in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after acquiring an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after acquiring an additional 2,801 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on IDXX shares. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Barclays decreased their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $523.86.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $432.34 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock has a market cap of $35.40 billion, a P/E ratio of 41.69, a PEG ratio of 3.60 and a beta of 1.36. The company has a 50-day moving average of $423.28 and a two-hundred day moving average of $456.85. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.53 earnings per share. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.